358 related articles for article (PubMed ID: 16563443)
1. mGlu1 and mGlu5 receptor antagonists lack anticonvulsant efficacy in rodent models of difficult-to-treat partial epilepsy.
Löscher W; Dekundy A; Nagel J; Danysz W; Parsons CG; Potschka H
Neuropharmacology; 2006 Jun; 50(8):1006-15. PubMed ID: 16563443
[TBL] [Abstract][Full Text] [Related]
2. Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats.
Pietraszek M; Sukhanov I; Maciejak P; Szyndler J; Gravius A; Wisłowska A; Płaźnik A; Bespalov AY; Danysz W
Eur J Pharmacol; 2005 May; 514(1):25-34. PubMed ID: 15878321
[TBL] [Abstract][Full Text] [Related]
3. Anticonvulsant effects of LY456236, a selective mGlu1 receptor antagonist.
Shannon HE; Peters SC; Kingston AE
Neuropharmacology; 2005; 49 Suppl 1():188-95. PubMed ID: 16011839
[TBL] [Abstract][Full Text] [Related]
4. Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling.
Klodzinska A; Tatarczyńska E; Chojnacka-Wójcik E; Nowak G; Cosford ND; Pilc A
Neuropharmacology; 2004 Sep; 47(3):342-50. PubMed ID: 15275823
[TBL] [Abstract][Full Text] [Related]
5. The influence of various glutamate receptors antagonists on anxiety-like effect of ethanol withdrawal in a plus-maze test in rats.
Kotlinska J; Bochenski M
Eur J Pharmacol; 2008 Nov; 598(1-3):57-63. PubMed ID: 18838071
[TBL] [Abstract][Full Text] [Related]
6. mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition.
Pietraszek M; Gravius A; Schäfer D; Weil T; Trifanova D; Danysz W
Neuropharmacology; 2005 Jul; 49(1):73-85. PubMed ID: 15992582
[TBL] [Abstract][Full Text] [Related]
7. The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety.
Busse CS; Brodkin J; Tattersall D; Anderson JJ; Warren N; Tehrani L; Bristow LJ; Varney MA; Cosford ND
Neuropsychopharmacology; 2004 Nov; 29(11):1971-9. PubMed ID: 15305166
[TBL] [Abstract][Full Text] [Related]
8. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W
Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428
[TBL] [Abstract][Full Text] [Related]
9. The role of group I mGlu receptors in the expression of ethanol-induced conditioned place preference and ethanol withdrawal seizures in rats.
Kotlinska JH; Bochenski M; Danysz W
Eur J Pharmacol; 2011 Nov; 670(1):154-61. PubMed ID: 21946112
[TBL] [Abstract][Full Text] [Related]
10. The role of group I metabotropic glutamate receptors in acquisition and expression of contextual and auditory fear conditioning in rats - a comparison.
Gravius A; Barberi C; Schäfer D; Schmidt WJ; Danysz W
Neuropharmacology; 2006 Dec; 51(7-8):1146-55. PubMed ID: 16905160
[TBL] [Abstract][Full Text] [Related]
11. The metabotropic glutamate 5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine reduces ethanol self-administration in multiple strains of alcohol-preferring rats and regulates olfactory glutamatergic systems.
Cowen MS; Djouma E; Lawrence AJ
J Pharmacol Exp Ther; 2005 Nov; 315(2):590-600. PubMed ID: 16014750
[TBL] [Abstract][Full Text] [Related]
12. Metabotropic glutamate receptor 1 blockade impairs acquisition and retention in a spatial Water maze task.
Steckler T; Oliveira AF; Van Dyck C; Van Craenendonck H; Mateus AM; Langlois X; Lesage AS; Prickaerts J
Behav Brain Res; 2005 Oct; 164(1):52-60. PubMed ID: 16043241
[TBL] [Abstract][Full Text] [Related]
13. Non-competitive metabotropic glutamate 1 receptor antagonists block activity of slowly adapting type I mechanoreceptor units in the rat sinus hair follicle.
Cahusac PM; Mavulati SC
Neuroscience; 2009 Oct; 163(3):933-41. PubMed ID: 19596050
[TBL] [Abstract][Full Text] [Related]
14. Anxiolytic-like action of MTEP expressed in the conflict drinking Vogel test in rats is serotonin dependent.
Stachowicz K; Gołembiowska K; Sowa M; Nowak G; Chojnacka-Wójcik E; Pilc A
Neuropharmacology; 2007 Nov; 53(6):741-8. PubMed ID: 17870136
[TBL] [Abstract][Full Text] [Related]
15. Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist.
Pałucha A; Brański P; Szewczyk B; Wierońska JM; Kłak K; Pilc A
Pharmacol Biochem Behav; 2005 Aug; 81(4):901-6. PubMed ID: 16040106
[TBL] [Abstract][Full Text] [Related]
16. Profile of SB-204269, a mechanistically novel anticonvulsant drug, in rat models of focal and generalized epileptic seizures.
Upton N; Blackburn TP; Campbell CA; Cooper D; Evans ML; Herdon HJ; King PD; Ray AM; Stean TO; Chan WN; Evans JM; Thompson M
Br J Pharmacol; 1997 Aug; 121(8):1679-86. PubMed ID: 9283703
[TBL] [Abstract][Full Text] [Related]
17. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy.
Stöhr T; Kupferberg HJ; Stables JP; Choi D; Harris RH; Kohn H; Walton N; White HS
Epilepsy Res; 2007 May; 74(2-3):147-54. PubMed ID: 17433624
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective activity of selective mGlu1 and mGlu5 antagonists in vitro and in vivo.
Szydlowska K; Kaminska B; Baude A; Parsons CG; Danysz W
Eur J Pharmacol; 2007 Jan; 554(1):18-29. PubMed ID: 17109843
[TBL] [Abstract][Full Text] [Related]
19. Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs.
Bruno V; Battaglia G; Copani A; D'Onofrio M; Di Iorio P; De Blasi A; Melchiorri D; Flor PJ; Nicoletti F
J Cereb Blood Flow Metab; 2001 Sep; 21(9):1013-33. PubMed ID: 11524608
[TBL] [Abstract][Full Text] [Related]
20. Selective mGlu5 receptor antagonist MTEP attenuates naloxone-induced morphine withdrawal symptoms.
Pałucha A; Brański P; Pilc A
Pol J Pharmacol; 2004; 56(6):863-6. PubMed ID: 15662102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
